Meanwhile, several pharmacological studies have also demonstrated that inhibition of NF-κB signaling pathway activation can play a therapeutic role in AD-like models in vivo and in vitro (17, 64–66). The gene discussed is NFKB1; the disease is Alzheimer disease.